Artesunate 2 — Competitive Intelligence Brief

Artesunate 2 (Artesunate 2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Artemisinin derivative. Area: Infectious Disease; Oncology.

marketed Artemisinin derivative Malaria parasite heme; potential cancer cell apoptosis pathways Infectious Disease; Oncology Small molecule

Target snapshot

Artesunate 2 (Artesunate 2) — University of Oxford. Artesunate is an artemisinin derivative that generates reactive oxygen species to kill malaria parasites and has immunomodulatory and anti-cancer properties.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Artesunate 2 TARGET	Artesunate 2	University of Oxford	marketed	Artemisinin derivative	Malaria parasite heme; potential cancer cell apoptosis pathways
artesunate (AS)	artesunate (AS)	London School of Hygiene and Tropical Medicine	marketed	Artemisinin derivative	Plasmodium heme and iron-dependent mechanisms
artesunate sachets	artesunate sachets	Pfizer	marketed	Artemisinin derivative	Plasmodium parasites (multiple targets including heme and parasite proteins)
Artesunate (Comparator)	Artesunate (Comparator)	Pfizer	marketed	Artemisinin derivative	Parasite proteins (non-specific alkylation via reactive oxygen species)
artesunate-amodiaquine (AS-AQ)	artesunate-amodiaquine (AS-AQ)	Yale University	marketed	Artemisinin derivative + aminoquinoline antimalarial combination	Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase
AS (Guilin Pharmaceuticals)	AS (Guilin Pharmaceuticals)	London School of Hygiene and Tropical Medicine	phase 3	Artemisinin derivative	Plasmodium heme-dependent activation
Artemether Sublingual Spray	Artemether Sublingual Spray	Proto Pharma Ltd	phase 3	Artemisinin derivative	Heme iron (parasite-derived); multiple parasite proteins and membranes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Artemisinin derivative class)

1. London School of Hygiene and Tropical Medicine · 2 drugs in this class
2. Pfizer · 2 drugs in this class
3. Proto Pharma Ltd · 1 drug in this class
4. University of Oxford · 1 drug in this class